Tomillero A, Moral M A
Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline mesilate, Recombinant human relaxin H2, rhGAD65, Rivaroxaban, Rosuvastatin calcium, Rotigotine; Saxagliptin, SCH-530348, Sirolimus-eluting stent, SLIT-amikacin, Sorafenib, Sotrastaurin, SR-16234, Sulforaphane; Tadalafil, Tanespimycin, Tapentadol hydrochloride, Teriparatide, Tesofensine, Tiotropium bromide, Tipifarnib, Tirapazamine, TMC-207, Tocilizumab, Tolvaptan, Tosedostat, Treprostinil sodium; Ustekinumab; Varespladib methyl, Vicriviroc, Vildagliptin, Vildagliptin/metformin hydrochloride, Volociximab, Voriconazole; Ziconotide, Ziprasidone hydrochloride.
《临床试验指南》是一份关于当前文献和会议中最新临床试验的指南。以下表格中的数据取自药物研发门户网站Prous Science Integrity的临床试验知识领域，网址为http://integrity.prous.com。本期聚焦以下药物：腺相关病毒1型/肌浆球蛋白Ca2+ -ATP酶2a、硫酸阿巴卡韦/拉米夫定、阿达木单抗、富马酸阿利吉仑、安立生坦、阿立哌唑、AT - 7519、硫酸阿扎那韦、盐酸托莫西汀、阿扎胞苷、阿折地平；盐酸贝西沙星、贝伐单抗、生物可吸收依维莫司洗脱冠状动脉支架、硼替佐米、波生坦、布地奈德/富马酸福莫特罗；CAIV - T、卡立普多、甲磺酸卡索匹坦、赛妥珠单抗、西妥昔单抗、环索奈德、环丙沙星/地塞米松、CTCE - 9908；达塞曲匹、达芦那韦、地拉罗司、地氯雷他定、双功能蛋白、重组活化蛋白C、DTA - H19、盐酸度洛西汀、度他雄胺；生态粒细胞刺激因子、依法利珠单抗、恩曲他滨、甲磺酸艾瑞布林、草酸艾司西酞普兰、右佐匹克隆、EUR - 1008、依维莫司洗脱冠状动脉支架、艾塞那肽；法吡拉西坦、糠酸氟替卡松、富马酸福莫特罗/丙酸氟替卡松、福沙普瑞那韦钙、氟维司群；加巴喷丁烯酯、GS - 7904L；人乳头瘤病毒6/11/16/18、人促胰液素、盐酸肼屈嗪/硝酸异山梨酯；甲磺酸伊马替尼、伊美克酮、伊纳利莫夫/法利莫夫、茚达特罗、马来酸茚达特罗、吸入型人胰岛素、德谷胰岛素、甘精胰岛素、伊沙匹隆；L - 丙氨酰谷氨酰胺、二甲苯磺酸拉帕替尼、来那度胺、二盐酸左西替利嗪、利拉鲁肽、甲磺酸赖氨酸安非他命、洛匹那韦、氯雷他定/孟鲁司特钠、α - 促黄体素；MeNZB、美泊利单抗、米卡芬净钠、盐酸吗啡；纳布西莫尔、尼可霉素Z；奥美沙坦酯、奥马珠单抗；紫杉醇洗脱支架、培非格司亭、聚乙二醇化干扰素α - 2a、聚乙二醇化干扰素α - 2b、哌立福辛、PF - 489791、普利替肽、泊沙康唑、普瑞巴林；QAX - 576；拉替拉韦钾、雷美替胺、甲磺酸雷沙吉兰、重组人松弛素H2、重组人谷氨酸脱羧酶65、利伐沙班、瑞舒伐他汀钙、罗替戈汀；沙格列汀、SCH - 530348、西罗莫司洗脱支架、SLIT - 阿米卡星、索拉非尼、索特拉司他汀、SR - 16234、萝卜硫素；他达拉非、坦西莫司、盐酸曲马多、特立帕肽、替索芬辛、噻托溴铵、替匹法尼、替拉扎明、TMC - 207、托珠单抗、托伐普坦、托西司他、曲前列尼尔钠；乌司奴单抗；瓦雷普拉德ib甲酯、维立西呱、维格列汀、维格列汀/盐酸二甲双胍、沃洛昔单抗、伏立康唑；齐考诺肽、盐酸齐拉西酮
